KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Operating Expenses: 2016-2024

Historic Other Operating Expenses for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to -$96.7 million.

  • Amneal Pharmaceuticals' Other Operating Expenses fell 88.64% to $117,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 104.77%. This contributed to the annual value of -$96.7 million for FY2024, which is 766.98% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Other Operating Expenses stood at -$96.7 million for FY2024, which was down 766.98% from $14.5 million recorded in FY2023.
  • Amneal Pharmaceuticals' 5-year Other Operating Expenses high stood at $14.5 million for FY2023, and its period low was -$269.9 million during FY2022.
  • In the last 3 years, Amneal Pharmaceuticals' Other Operating Expenses had a median value of -$96.7 million in 2024 and averaged -$117.4 million.
  • In the last 5 years, Amneal Pharmaceuticals' Other Operating Expenses crashed by 979.72% in 2022 and then soared by 105.37% in 2023.
  • Amneal Pharmaceuticals' Other Operating Expenses (Yearly) stood at -$5.9 million in 2020, then tumbled by 326.62% to -$25.0 million in 2021, then plummeted by 979.72% to -$269.9 million in 2022, then skyrocketed by 105.37% to $14.5 million in 2023, then plummeted by 766.98% to -$96.7 million in 2024.